KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Deferred Tax Liability (2025)

Pacira BioSciences has reported Non-Current Deferred Tax Liability over the past 1 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $4.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $4.2 million (changed N/A YoY), and the annual figure for FY2025 was $4.2 million, changed.
  • Non-Current Deferred Tax Liability for Q4 2025 was $4.2 million at Pacira BioSciences, down from $4.6 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for PCRX hit a ceiling of $7.0 million in Q1 2025 and a floor of $4.2 million in Q4 2025.